Press Releases
 
Secondary Hyperparathyroidism Treatment Market Report 2016 and Future Opportunity Assessment 2024

, 26 March 2019 -- Secondary hyperparathyroidism is a disease that affects the parathyroid glands, leading to an increased production of parathyroid hormone (PTH) to maintain normal calcium levels in the blood. The disease is caused by an underlying chronic kidney disease in which the phosphorus in the blood is not cleaned by the kidneys. This excess phosphorus in the blood leads to a decline in calcium levels causing secondary hyperparathyroidism. In the early stages of secondary hyperparathyroidism, the PTH levels are high though the calcium levels are low or normal. The high levels of PTH lead to cardiovascular complications, low blood count, abnormal fat and sugar metabolism, weakening of bones, and calciphylaxis. The other causes of secondary hyperparathyroidism include vitamin D deficiency, vitamin D-resistant rickets, high abnormal levels of magnesium, malnutrition, and gastrointestinal malabsorption syndrome.

Read Report Overview:
https://www.transparencymarketresearch.com/secondary-hyperparathyroidism-treatment-market.html

Growth in prevalence of chronic kidney disease, which is a leading cause of secondary hyperparathyroidism, is one of the primary reasons for the growth of the secondary hyperparathyroidism treatment market. In addition, increase in research activities on the disease and rise in product approvals contribute to the growth of the market. For instance, in 2016, Amgen’s Parsabiv (etelcalcetide) was granted marketing authorization in Europe for the treatment of secondary hyperparathyroidism in ##### patients with chronic kidney disease on hemodialysis. Furthermore, the growing number of products in the pipeline drives the market growth. However, the side effects associated with the secondary hyperparathyroidism treatment such as diarrhea, vomiting, muscle spasm, and decrease in serum calcium might have a negative impact on the market. Furthermore, decrease in the serum calcium levels as a result of the treatment leads to increased risk of heart failure owing to hypotension and decreased myocardial performance.

The secondary hyperparathyroidism treatment market can be segmented based on treatment type, distribution channel, and geography. On the basis of treatment type, the market can be segmented into surgery and drug class. The drug class can be further sub-segmented into vitamin D and derivatives, calcimimetics, and phosphate binders. Among the drug class, calcimimetics are anticipated to record a significant growth owing to their ability to bind to parathyroid cell receptors and decrease the level of calcium in blood serum. Furthermore, the increasing product approvals of calcimimetics contribute to the rapid growth of the segment. On the basis of distribution channel, the market can be segmented into hospital pharmacies and retail pharmacies. The hospital pharmacies segment is anticipated to dominate the market during the forecast period.

Geographically, the secondary hyperparathyroidism treatment market is distributed over North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to record a significant market share of the secondary hyperparathyroidism treatment. This can be attributed to the well-developed health care infrastructure, growth in awareness among people, and favorable reimbursement scenarios. Europe is anticipated to be the trailing next region in the market. However, the market growth in the region is anticipated to be affected owing to the sluggish economic growth. The Asia Pacific market is expected to record a robust CAGR during the forecast period. This growth can be attributed to the significant contribution from the emerging countries such as China and India. The high prevalence of chronic kidney disease in the region further drives the growth of the market.

Request Brochure of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20600

The leading players operating in the secondary hyperparathyroidism treatment market include Amgen Inc., OPKO Health, Inc., AbbVie Inc., Shire Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc, KAI Pharmaceuticals, Leo Pharma A/S, and Deltanoid Pharmaceuticals.

About us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
Website: https://www.transparencymarketresearch.com/



# # #


Submitted by hawer on Tuesday, 26 March 2019 at 4:04 AM
Category: Health Care & Medical
 
Related News

Global Smoke Evacuation System Market | Growth, Trends and Forecast Till 2024
Monday, 22 Apr 2019

Dr. Garg’s Multispeciality Dental Centre is Enhancing Smiles with Tooth Jewellery
Monday, 22 Apr 2019

Coronary Stents Market: Increase in Geriatric Population to Drive Demand
Friday, 19 Apr 2019

Wearable Medical Devices Market - Rising Number of Sports and Fitness Enthusiasts to Boost the Deman
Friday, 19 Apr 2019

Catheters Market - Increasing Demand for Minimally Invasive Surgeries to Spur the Demand
Friday, 19 Apr 2019

Related Events

3rd Annual NASH Summit | April 22-25, 2019 | Boston, MA
Monday, 22 Apr 2019

Rx Drug Abuse and Heroin Summit
Monday, 22 Apr 2019

European NeoAg Summit 2019
Tuesday, 23 Apr 2019

MASS East
Wednesday, 24 Apr 2019

8th Digital Marketing for Medical Devices West
Wednesday, 24 Apr 2019

Latest News

A Guide To Clairvoyance
Monday, 22 Apr 2019

Plumbing Companies - 6 Tips for Picking out the best Plumbing Company
Monday, 22 Apr 2019

Meat Alternatives Market will Rise at a 6.1% CAGR over 2018 to 2026
Monday, 22 Apr 2019

Ready-to-Drink Coffee Market Expected to Grow at a CAGR of 7.7% During 2018-2026
Monday, 22 Apr 2019

Boomer Real Estate Investing – Experts in the Investment Domain
Monday, 22 Apr 2019

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2019
Today is Monday, 22 April 2019

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • 3rd Annual NASH Summit | April 22-25, 2019 | Boston, MA
  • Rx Drug Abuse and Heroin Summit
  • European NeoAg Summit 2019
  • 46th IOP Plasma Physics Conference, Loughborough, UK
  • Transformational CISO Assembly in Nashville - April 2019

  • Latest Jobs
    Sorry, there are currently no entries posted here.